Skip to content

Consumption of Whole Grains and Legumes Modulates the Genetic Effect of the APOA5 -1131C Variant

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01784952
Enrollment
200
Registered
2013-02-06
Start date
2012-01-31
Completion date
2012-10-31
Last updated
2013-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects With Mild Hypertriglyceridemia in Type 2 DM

Brief summary

We examined whether a substitution of whole grains and legumes for refined rice in a high carbohydrate diet (about 65% of energy derived from carbohydrate) may modify the effect of this variant on changes in apolipoprotein A-V (apoA-V) and triglyceride concentrations.

Detailed description

We genotyped the APOA5 -1131T\>C in individuals with impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes, who were randomly assigned to either a group ingesting whole grain and legume meals daily or a control group for 12 weeks.

Interventions

DIETARY_SUPPLEMENTDietary intervention

The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 72 Years
Healthy volunteers
No

Inclusion criteria

* Subjects who were in in impaired fasting glucose (IFG, 100≤ fasting glucose \<126 mg/dL) and newly diagnosed type 2 diabetes (fasting glucose ≥126 mg/dL) were referred to the Department of Family Medicine or Internal Medicine. They were rechecked for their health and lipid profiles, and then those who satisfied the study criteria were recommended to participate in the dietary intervention program

Exclusion criteria

* Current and/or past history of cardiovascular disease including angina * Liver or kidney dysfunction * Thyroid or pituitary disease * Unstable weight loss/gain (≥2 kg) over the previous 6months * Pregnancy or lactation. Subjects who were taking medication were also excluded

Design outcomes

Primary

MeasureTime frame
Triglyceridechange from baseline in TG at 12 weeks

Secondary

MeasureTime frame
Apolipoprotein A5Change from baseline in ApoA5 at 12 weeks

Other

MeasureTime frame
Apolipoprotein A5 geneApoA5 -1131T>C polymorphism

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026